具有抗结核活性的新型AHAS抑制剂
详细信息    查看官网全文
摘要
随着多药耐药(MDR)和广泛耐药(XDR)的结核分枝杆菌的出现,结核病又成为人类面临的重大疾病。近年来研究表明,乙酰乳酸合成酶(AHAS)可以作为抗结核(TB)药物的新靶点~1。我们同源蛋白模建了TB-AHAS的结构,经过虚拟筛选,发现了一类喹唑啉酮酸酯类化合物具有较好的抗结核活性~2。据此设计合成了20余个新结构的取代苯甲酸喹唑啉酮酸酯类化合物,不仅具有较好的TB-AHAS抑制活性,也具有较高的抗结核菌活性,对MDR和XDR结核菌都有明显效果~3。
Mycobacterium tuberculosis(MTB) infection has become an increasing health threat due to the worldwide emergence of multidrug-resistant MTB(MDR-MTB) and extensively drug-resistant MTB(XDR-MTB).Recent study showed that acetohydroxyacid synthase(AHAS,E.C.2.2.1.6) could be considered as a novel target for anti-MTB agents~1.Some quinazolinone benzoates were discovered to have anti-MTB activity via virtual screening of AHAS binding site~2.Based on this,we designed and synthesized more than twenty substituted quinazolinone benzoates and evaluated their biological activity.These compounds not only showed good inhibition against MTB-AHAS,but also exhibited potent anti-tuberculosis activity,including MDR and XDR tuberculosis strains~3.
引文
[1]Grandoni,J.A.;Marta,P.T.;Schloss,J.V.J.Antimicrob.Chemother.1998,42:475.
    [2]Wang,D.;Zhu,X.;Cui,C;Dong,M.;Jiang,H.;Li,Z.;Liu,Z.;Zhu,W.;Wang,J.G.J.Chem.Inf.Model.2013,53:343.
    [3]Lu,W.;Baig,I.A.;Sun,H.J.;Cui,C.J.;Guo,R.;Jung,I.P.;Wang,D.;Dong,M.;Yoon,M.Y.;Wang,J.G.Eur.J.Med.Chem.2015,94:298

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700